Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Efficacy of Nanofat in Wound Healing: A Double-Blinded Randomized Controlled Trial.

Wongkietkachorn A., Wongkietkachorn N.

Randomized Controlled Trial on Chronic Wound, Scar, published in Plast Reconstr Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Plast Reconstr Surg (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41055340
PMCID
PMC13200879
DOI
10.1097/PRS.0000000000012507
Citations
2

Abstract (original English)

Nanofat has been shown to contain a variety of growth factors, antiinflammatory mediators, and adipose-derived stem cells, all of which may significantly contribute to the wound healing process. However, there is limited comparative clinical evidence supporting its use. This study aims to evaluate the effects of nanofat on wound healing in abdominoplasty by comparing outcomes between nanofat-treated and -nontreated wounds. A double-blinded randomized controlled trial was conducted using a split-wound model. Each wound was divided and randomized into a nanofat-treated side and a nonnanofat-treated control side. Nanofat was prepared and injected along the wound margins using a standardized dose. Both patients and the surgeons evaluating the wounds were blinded to the treatment allocation. Wound outcomes were assessed 6 months postoperatively using the Observer Scale of the Patient and Observer Scar Assessment Scale. Fifty lipoabdominoplasty patients were included in the study. Wound outcomes were significantly better in the nanofat group compared with the nonnanofat group across all assessed parameters, including vascularity, pigmentation, thickness, relief, pliability, surface area, and overall opinion ( P < 0.001). No oil cysts or fat necrosis were observed in the nanofat group. Nanofat significantly improved wound outcomes in abdominoplasty patients without associated complica

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansDouble-Blind MethodWound HealingFemaleAdultTreatment OutcomeMiddle AgedMaleLipoabdominoplasty

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research